The FDA has issued a complete response letter to the supplemental new drug application seeking the full approval of sotorasib for patients with KRAS G12C–mutated non–small cell lung cancer.
Adagrasib induced high overall response rates in patients with KRAS G12C–mutated non–small cell lung cancer who achieved at least 90% mutation allele frequency clearance.